{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T16:01:41Z","timestamp":1786550501480,"version":"build-2736575974"},"reference-count":30,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,17]],"date-time":"2024-09-17T00:00:00Z","timestamp":1726531200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Farmacia Hospitalaria"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.farma.2024.09.006","type":"journal-article","created":{"date-parts":[[2024,10,18]],"date-time":"2024-10-18T14:12:48Z","timestamp":1729260768000},"page":"T17-T23","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["[Translated article] Real-world effectiveness and safety of nivolumab in patients with relapsed or refractory classical Hodgkin lymphoma"],"prefix":"10.1016","volume":"49","author":[{"given":"Laura","family":"Lorente Fern\u00e1ndez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Romero Dom\u00ednguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asunci\u00f3n","family":"Albert Mar\u00ed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esperanza","family":"N\u00fa\u00f1ez Benito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"L\u00f3pez Briz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Luis","family":"Poveda Andr\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.farma.2024.09.006_bb0005","doi-asserted-by":"crossref","first-page":"162","DOI":"10.14694\/EdBook_AM.2012.32.83","article-title":"Targeting CD30 in hodgkin lymphoma: antibody-drug conjugates make a difference","author":"Diefenbach","year":"2012","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"11","key":"10.1016\/j.farma.2024.09.006_bb0010","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1002\/ajh.26717","article-title":"Hodgkin lymphoma: 2023 update on diagnosis, risk-stratification, and management","volume":"97","author":"Ansell","year":"2022","journal-title":"Am J Hematol."},{"key":"10.1016\/j.farma.2024.09.006_bb0015","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1182\/asheducation-2013.1.394","article-title":"Novel therapy for Hodgkin lymphoma","volume":"2013","author":"Batlevi","year":"2013","journal-title":"Haematol Am Soc Hematol Educ Program."},{"issue":"10","key":"10.1016\/j.farma.2024.09.006_bb0020","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/j.bbmt.2006.06.006","article-title":"Long-term results of autologous stem cell transplantation for primary refractory or relapsed Hodgkin's lymphoma","volume":"12","author":"Majhail","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"10.1016\/j.farma.2024.09.006_bb0025","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1093\/annonc\/mdi119","article-title":"Grupo Espa\u00f1ol de Linfomas\/Trasplante Aut\u00f3logo de M\u00e9dula Osea Cooperative Group. Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin's lymphoma autografted after a first relapse","volume":"16","author":"Sureda","year":"2005","journal-title":"Ann Oncol."},{"issue":"11","key":"10.1016\/j.farma.2024.09.006_bb0030","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.3109\/10428194.2013.798868","article-title":"Defining a Hodgkin lymphoma population for novel therapeutics after relapse from autologous haematopoietic cell transplant","volume":"54","author":"Arai","year":"2013","journal-title":"Leuk Lymphoma."},{"issue":"9323","key":"10.1016\/j.farma.2024.09.006_bb0035","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1016\/S0140-6736(02)08938-9","volume":"359","author":"Schmitz","year":"2002","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.farma.2024.09.006_bb0040","doi-asserted-by":"crossref","first-page":"310","DOI":"10.3324\/haematol.2011.045757","volume":"97","author":"Sureda","year":"2012","journal-title":"Haematologica"},{"issue":"Suppl 4","key":"10.1016\/j.farma.2024.09.006_bb0045","doi-asserted-by":"crossref","first-page":"iv19","DOI":"10.1093\/annonc\/mdy080","article-title":"ESMO Guidelines Committee. Hodgkin lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Eichenauer","year":"2018","journal-title":"Ann Oncol."},{"issue":"13","key":"10.1016\/j.farma.2024.09.006_bb0050","doi-asserted-by":"crossref","first-page":"3462","DOI":"10.1158\/1078-0432.CCR-13-0855","article-title":"PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies","volume":"19","author":"Chen","year":"2013","journal-title":"Clin Cancer Res."},{"key":"10.1016\/j.farma.2024.09.006_bb0055","author":"Ficha T\u00e9cnica de Opdivo"},{"key":"10.1016\/j.farma.2024.09.006_bb0060","author":"European Public Assessment Report (EPAR) de Opdivo\u00ae"},{"issue":"9","key":"10.1016\/j.farma.2024.09.006_bb0065","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/S1470-2045(16)30167-X","article-title":"Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial","volume":"17","author":"Younes","year":"2016","journal-title":"Lancet Oncol."},{"issue":"14","key":"10.1016\/j.farma.2024.09.006_bb0070","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1200\/JCO.2017.76.0793","article-title":"Nivolumab for relapsed\/refractory classic Hodgkin lymphoma after failure of autologous haematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase II CheckMate 205 trial","volume":"36","author":"Armand","year":"2018","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.farma.2024.09.006_bb0075","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1038\/s41375-021-01193-6","article-title":"Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma","volume":"35","author":"Merryman","year":"2021","journal-title":"Leukaemia"},{"issue":"36","key":"10.1016\/j.farma.2024.09.006_bb0080","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.farma.2024.09.006_bb0085","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s12094-019-02273-x","article-title":"SEOM clinical guideline for the management of immune-related adverse events in patients treated with immune checkpoint inhibitors (2019)","volume":"22","author":"Majem","year":"2020","journal-title":"Clin Transl Oncol."},{"issue":"2","key":"10.1016\/j.farma.2024.09.006_bb0090","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1182\/blood-2017-01-761346","article-title":"PD-1 blockade for relapsed lymphoma post-allogeneic haematopoietic cell transplant: high response rate but frequent GVHD","volume":"130","author":"Haverkos","year":"2017","journal-title":"Blood"},{"issue":"27","key":"10.1016\/j.farma.2024.09.006_bb0095","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"issue":"21","key":"10.1016\/j.farma.2024.09.006_bb0100","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1182\/blood-2016-05-718528","article-title":"Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy","volume":"128","author":"Cheson","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.farma.2024.09.006_bb0105","series-title":"Common Terminology Criteria for Adverse Events (CTCAE) version 5.0","year":"2017"},{"issue":"10","key":"10.1016\/j.farma.2024.09.006_bb0110","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1093\/annonc\/mdx341","article-title":"Nivolumab for relapsed or refractory Hodgkin lymphoma: real-life experience","volume":"28","author":"Bek\u00f6z","year":"2017","journal-title":"Ann Oncol."},{"issue":"suppl 1","key":"10.1016\/j.farma.2024.09.006_bb0115","first-page":"5171","article-title":"Real-world data of nivolumab in classical Hodgkin lymphoma: results from the Italian expanded access programme","volume":"130","author":"Santoro","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.farma.2024.09.006_bb0120","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ejca.2019.04.006","article-title":"Long-term efficacy of anti-PD1 therapy in Hodgkin lymphoma with and without allogenic stem cell transplantation","volume":"115","author":"Manson","year":"2019","journal-title":"Eur J Cancer."},{"issue":"7","key":"10.1016\/j.farma.2024.09.006_bb0125","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1634\/theoncologist.2018-0538","article-title":"Outcomes and toxicities of programmed death-1 (PD-1) inhibitors in Hodgkin lymphoma patients in the United States: a real-world, multicenter retrospective analysis","volume":"24","author":"Bair","year":"2019","journal-title":"Oncologist"},{"issue":"8","key":"10.1016\/j.farma.2024.09.006_bb0130","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1016\/j.bbmt.2020.02.003","article-title":"Potential survival benefit for patients receiving allogeneic haematopoietic stem cell transplantation after nivolumab therapy for relapse\/refractory hodgkin lymphoma: real-life experience in Spain","volume":"26","author":"Mart\u00ednez","year":"2020","journal-title":"Biol Blood Marrow Transplant."},{"key":"10.1016\/j.farma.2024.09.006_bb0135","doi-asserted-by":"crossref","DOI":"10.1177\/20406207211038181","article-title":"Addition of chemotherapy to nivolumab after PD-1 inhibitor failure as bridge to allogeneic stem cell transplantation in classical Hodgkin's lymphoma: report on three cases and literature review","volume":"12","author":"Romero","year":"2021","journal-title":"Ther Adv Hematol."},{"key":"10.1016\/j.farma.2024.09.006_bb0140","doi-asserted-by":"crossref","DOI":"10.1002\/ajh.25154","article-title":"Efficacy of chemotherapy or chemo-anti-PD-1 combination after failed anti-PD-1 therapy for relapsed and refractory Hodgkin lymphoma: a series from Lysa centers","author":"Rossi","year":"2018","journal-title":"Am J Hematol."},{"issue":"3","key":"10.1016\/j.farma.2024.09.006_bb0145","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000401","article-title":"A study of safety and efficacy of nivolumab and bendamustine (NB) in patients with relapsed\/refractory hodgkin lymphoma after nivolumab monotherapy failure","volume":"4","author":"Lepik","year":"2020","journal-title":"Hemasphere"},{"key":"10.1016\/j.farma.2024.09.006_bb0150","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.17_suppl.LBA4","article-title":"SWOG S1826, a randomised study of nivolumab(N)-AVD versus brentuximab vedotin(BV)-AVD in advanced stage (AS) classic Hodgkin lymphoma (HL)","volume":"41","author":"Herrera","year":"2023","journal-title":"J Clin Oncol"}],"container-title":["Farmacia Hospitalaria"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1130634324001557?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1130634324001557?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,18]],"date-time":"2025-01-18T15:05:06Z","timestamp":1737212706000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1130634324001557"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S1130634324001557"],"URL":"https:\/\/doi.org\/10.1016\/j.farma.2024.09.006","relation":{},"ISSN":["1130-6343"],"issn-type":[{"value":"1130-6343","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"[Translated article] Real-world effectiveness and safety of nivolumab in patients with relapsed or refractory classical Hodgkin lymphoma","name":"articletitle","label":"Article Title"},{"value":"Farmacia Hospitalaria","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.farma.2024.09.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.farma.2024.04.020","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Espa\u00f1a, S.L.U. on behalf of Sociedad Espa\u00f1ola de Farmacia Hospitalaria (S.E.F.H).","name":"copyright","label":"Copyright"}]}}